The European Patent Office (EPO) has issued an intention to grant a patent for Vistagen’s new PH80 nasal spray to treat migraine.

The patent’s claims also include treatment given at the onset of migraine symptoms as well as the treatment of migraines associated with traumatic brain injury.

The patent will remain active until at least 2040.

PH80 is a first-in-class, rapid-onset nasal spray designed to be used in a similar way to a rescue asthma inhaler.

It offers patient-tailored, user-friendly, intranasal administration as required, up to multiple times a day.

PH80 has a potential rapid-onset mechanism of action (MOA) which is fundamentally differentiated from all existing approved treatments for migraine.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The therapy’s MOA does not need systemic exposure or direct action on the neurons of the central nervous system (CNS) to create a therapeutic effect.

This is a significant potential treatment advantage over traditional pharmaceuticals, including existing migraine treatments.

The new nasal spray works by initiating neural impulses in the olfactory bulb that quickly affect the functioning of multiple structures in the brain connected to migraine pathology, including the amygdala and hypothalamus.

In March 2023, PH80 nasal spray received a patent from the US Patent and Trademark Office (USPTO) to treat migraine.

Vistagen stated that the PH80 development programme focuses on the acute treatment of migraine and also on the management of menopausal hot flushes.